Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Non-Current Deffered Revenue (2020 - 2025)

Historic Non-Current Deffered Revenue for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $1.8 million.

  • Caribou Biosciences' Non-Current Deffered Revenue fell 5551.05% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 5551.05%. This contributed to the annual value of $3.3 million for FY2024, which is 4564.08% down from last year.
  • According to the latest figures from Q3 2025, Caribou Biosciences' Non-Current Deffered Revenue is $1.8 million, which was down 5551.05% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Non-Current Deffered Revenue ranged from a high of $24.2 million in Q2 2021 and a low of $1.8 million during Q3 2025
  • Over the past 5 years, Caribou Biosciences' median Non-Current Deffered Revenue value was $10.3 million (recorded in 2023), while the average stood at $11.2 million.
  • In the last 5 years, Caribou Biosciences' Non-Current Deffered Revenue soared by 225133.4% in 2021 and then tumbled by 7465.04% in 2024.
  • Caribou Biosciences' Non-Current Deffered Revenue (Quarter) stood at $22.0 million in 2021, then decreased by 27.59% to $16.0 million in 2022, then crashed by 61.75% to $6.1 million in 2023, then tumbled by 45.64% to $3.3 million in 2024, then crashed by 47.06% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $1.8 million for Q2 2025, and $2.6 million during Q1 2025.